Clinical trial
A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT05622708 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- March 28, 2023
- Completion date
- April 4, 2028
- Enrollment
- 240 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.